Back to List View Graph View

Met

MET, also known as c-Met, is a receptor tyrosine kinase that functions as the cell-surface receptor for hepatocyte growth factor.

Where the papers sit

10 papers from the last 6 months study met directly · updated from PubMed 15 Nov 2026

  • Molecular Biomarkers in Carcinoma

    Molecular profiling is moving from isolated immunohistochemical markers toward integrated testing that guides targeted treatment across carcinomas. Preanalytical variation and small bronchoscopic samples remain important limits for reliable lung-cancer classification. MET expression is being evaluated for prognosis and anti-MET antibody-drug conjugates in upper gastrointestinal adenocarcinoma, while ERBB2, HER2 and EGFR recur as actionable markers. Amivantamab extends targeted therapy into recurrent or metastatic head and neck cancer after checkpoint blockade and chemotherapy.

    5 papers · 50%

  • Computational Cancer Biology

    Computational analyses are linking cancer phenotypes to regulatory programs and diagnostic biomarkers. Luteolin is associated with reduced glucose uptake, colony formation and malignant behavior in pancreatic ductal adenocarcinoma cells. Weighted gene co-expression and machine-learning approaches highlight cell-cycle and mitotic-spindle programs in colorectal cancer. AI-based detection of PTPRZ1-MET fusion points toward molecular classification of secondary glioblastoma.

    3 papers · 30%

  • Gut–Immune Signaling in Disease

    Gut microbiota and immune networks are being treated as connected drivers of inflammatory disease rather than separate targets. Endometriosis analyses emphasize Bifidobacterium, Bacteroides and molecular immune niches identified through multi-omics integration. Irritable bowel syndrome research uses network pharmacology to map Magnolia officinalis onto multiple inflammatory pathways and targets. The work remains largely mechanistic and computational, with therapeutic validation still open.

    2 papers · 20%

NEW DIRECTION

MET is proposed as a protective immune–microbiota hub in endometriosis rather than solely as a cancer-associated target

The endometriosis integrative multi-omics and network-analysis study identified MET as a hub gene with a potentially protective association, linking it to gut microbiota-derived metabolites and immune and inflammatory pathways involved in lesion formation 42713565Sep. This assigns MET a host regulatory role in a nonmalignant, hormone-dependent inflammatory disease, unlike the other papers’ use of MET as an oncogenic driver, biomarker, or therapeutic target in cancer. If validated, the finding shifts MET from being viewed only as a molecule to inhibit or detect toward a factor whose activity may help constrain disease-associated immune and microbial processes.

Papers

The 10 papers from the last 6 months that study met directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Molecular Biomarkers in Carcinoma (5)
  1. Preanalytical variables affect predictive immunohistochemical biomarker testing in non-small cell lung carcinoma cytology specimens. Cancer cytopathology · 9 Oct 2026 PMID 42851084
  2. SMARCA2 and SMARCA4-deficiency is associated with a distinct molecular and microenvironmental subtype of esophageal adenocarcinoma. Scientific reports · 29 Jul 2026 PMID 42527418
  3. Integrated prediction of lung cancer histology and molecular profiles from small bronchoscopic tumor specimens. NPJ precision oncology · 27 Jul 2026 PMID 42509268
  4. MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti-MET Antibody-Drug Conjugate Therapy. International journal of cancer · 3 Jul 2026 PMID 42394136
  5. Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 31 May 2026 PMID 42218660
Computational Cancer Biology (3)
  1. Artificial intelligence-based diagnostic model for identifying PTPRZ1-MET fusion in a clinically defined secondary glioblastoma cohort. Molecular biomedicine · 3 Aug 2026 PMID 42547688
  2. Luteolin reduces glucose uptake and malignant phenotypes in pancreatic ductal adenocarcinoma cells: an integrated bioinformatics and in vitro study. Biochemical and biophysical research communications · 26 Jul 2026 PMID 42503269
  3. Investigating the mechanisms of malignant progression in colorectal cancer using weighted gene co-expression network analysis and machine learning. Journal of molecular histology · 18 Jul 2026 PMID 42470494
Gut–Immune Signaling in Disease (2)
  1. Immune regulatory networks and gut microbiota-associated targets in endometriosis: an integrative multi-omics and network analysis. Open life sciences · 9 Sept 2026 PMID 42713565
  2. Deciphering the multi-target mechanism of Magnolia officinalis in irritable bowel syndrome with diarrhea: A combined network pharmacology, machine learning, and in vivo validation study. Biochemical and biophysical research communications · 23 May 2026 PMID 42176387

By study type

Clinical trials (1)
  1. Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 31 May 2026 PMID 42218660
Observational studies and case reports (2)
  1. Preanalytical variables affect predictive immunohistochemical biomarker testing in non-small cell lung carcinoma cytology specimens. Cancer cytopathology · 9 Oct 2026 PMID 42851084
  2. Artificial intelligence-based diagnostic model for identifying PTPRZ1-MET fusion in a clinically defined secondary glioblastoma cohort. Molecular biomedicine · 3 Aug 2026 PMID 42547688
Human data, design not indexed (2)
  1. SMARCA2 and SMARCA4-deficiency is associated with a distinct molecular and microenvironmental subtype of esophageal adenocarcinoma. Scientific reports · 29 Jul 2026 PMID 42527418
  2. MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti-MET Antibody-Drug Conjugate Therapy. International journal of cancer · 3 Jul 2026 PMID 42394136
Preclinical: animal, cell and lab studies (3)
  1. Luteolin reduces glucose uptake and malignant phenotypes in pancreatic ductal adenocarcinoma cells: an integrated bioinformatics and in vitro study. Biochemical and biophysical research communications · 26 Jul 2026 PMID 42503269
  2. Investigating the mechanisms of malignant progression in colorectal cancer using weighted gene co-expression network analysis and machine learning. Journal of molecular histology · 18 Jul 2026 PMID 42470494
  3. Deciphering the multi-target mechanism of Magnolia officinalis in irritable bowel syndrome with diarrhea: A combined network pharmacology, machine learning, and in vivo validation study. Biochemical and biophysical research communications · 23 May 2026 PMID 42176387
Unclassified: not yet indexed with MeSH (2)
  1. Immune regulatory networks and gut microbiota-associated targets in endometriosis: an integrative multi-omics and network analysis. Open life sciences · 9 Sept 2026 PMID 42713565
  2. Integrated prediction of lung cancer histology and molecular profiles from small bronchoscopic tumor specimens. NPJ precision oncology · 27 Jul 2026 PMID 42509268